Advanced search
Start date
Betweenand

Therapeutic vaccine based on aDC1 dendritic cells pulsed with inactivated autologous virus for the control of viremia after ATI in HIV infected individuals

Grant number: 16/25212-9
Support type:Research Projects - Thematic Grants
Duration: June 01, 2018 - May 31, 2023
Field of knowledge:Biological Sciences - Immunology
Principal Investigator:Alberto José da Silva Duarte
Grantee:Alberto José da Silva Duarte
Home Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo, SP, Brazil
Co-Principal Investigators:Luís Fernando de Macedo Brígido
Assoc. researchers:Alessandra Pontillo ; Alexandre de Almeida ; Bosco Christiano Maciel da Silva ; Bruna Tereso Santillo ; Luanda Mara da Silva Oliveira ; Paula Ordonhez Rigato ; Robbie B. Mailliard ; Telma Miyuki Oshiro Sumida
Associated scholarship(s):18/12460-0 - Production and characterization of polarized dendritic cells aDC1 for use in anti-HIV immunotherapy, BP.PD

Abstract

Dendritic cell based immunotherapy is a potential tool to stimulate a specific immune response, as a complementary treatment for HIV-infected individuals using ART. Polarizing DCs are capable to produce high levels of IL-12p70 and induce a strong cytotoxic response that is very useful in viral infections. In this context, we propose to study aDC1 pulsed with autologous inactivated virus for treatment of HIV infected individuals. The study will include 30 diagnosed HIV-infected patients not ART treated at inclusion time. Six months after treatment initiation they will be immunized or not with aDC1 according to the arms of this study: G1) placebo control/without ART interruption; G2) aDC1immunization/without ART interruption; G3) aDC1 immunization/analytical treatment interruption. Autologous PBMCs will be collected for virus isolation and patients will start ART. Waiting for 24 weeks for PVL going below detection, samples will be collected for baseline parameters and vaccine will be inoculated in 3 doses (with a fortnight interval). Three weeks after 3th vaccine inoculation, ART will be interrupted only for G3 patients. Patients will be followed for more 12 weeks and blood and biopsis (jejunum) samples will be collected for different parameters measurement as immune activation, immunogenecity, humoral response, mucosal cellular immunity and virologic profile and viral reservoir analysis. (AU)